RenovoRx (NASDAQ:RNXT) Releases Quarterly Earnings Results, Meets Estimates

RenovoRx (NASDAQ:RNXT – Get Free Report) issued its quarterly earnings data on Thursday. The company reported ($0.08) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.08), FiscalAI reports. RenovoRx had a negative return on equity of 119.77% and a negative net margin of 994.48%.The business had revenue of $0.56 million during the quarter, compared to analyst estimates of $0.47 million.

Here are the key takeaways from RenovoRx’s conference call:

Get RenovoRx alerts:

• RenovoRx reported record Q1 2026 revenue of $563,000, up 136% sequentially from Q4 2025 and more than half of full-year 2025 revenue, signaling that its commercial model is starting to scale.
• The company said it now has 16 active commercial cancer centers as of May 2026, up from 8 at year-end 2025, with 32 more centers in the pipeline and a target of 36 centers by year-end.
• Management reiterated full-year 2026 revenue guidance of $3 million to $4 million and said second-quarter revenue is tracking above Q1, which they believe keeps them on plan.
• The TIGeR-PaC Phase III trial is nearing enrollment completion, with 106 of 114 patients randomized and enrollment expected to close in early June, while final data remains expected in mid-to-late 2027.
• RenovoRx completed an oversubscribed $10 million private placement and ended Q1 with $12.4 million in cash, giving it runway into the second half of 2027 as it works toward cash flow breakeven.

RenovoRx Price Performance

Shares of RNXT traded down $0.04 during mid-day trading on Friday, hitting $0.82. 647,593 shares of the company’s stock were exchanged, compared to its average volume of 328,149. The company has a market cap of $36.94 million, a PE ratio of -2.56 and a beta of 1.00. RenovoRx has a 52 week low of $0.70 and a 52 week high of $1.45. The company has a 50-day simple moving average of $0.94 and a 200 day simple moving average of $0.94.

Hedge Funds Weigh In On RenovoRx

Several hedge funds have recently made changes to their positions in the business. XTX Topco Ltd grew its stake in shares of RenovoRx by 58.6% during the 4th quarter. XTX Topco Ltd now owns 50,140 shares of the company’s stock worth $42,000 after acquiring an additional 18,525 shares in the last quarter. Geode Capital Management LLC boosted its holdings in shares of RenovoRx by 9.9% in the 2nd quarter. Geode Capital Management LLC now owns 353,603 shares of the company’s stock valued at $467,000 after buying an additional 31,730 shares during the last quarter. Bleichroeder LP boosted its holdings in shares of RenovoRx by 11.4% in the 4th quarter. Bleichroeder LP now owns 600,000 shares of the company’s stock valued at $504,000 after buying an additional 61,379 shares during the last quarter. Northwestern Mutual Wealth Management Co. acquired a new stake in shares of RenovoRx in the 2nd quarter valued at approximately $98,000. Finally, Citadel Advisors LLC acquired a new stake in shares of RenovoRx in the 3rd quarter valued at approximately $154,000. 3.10% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities analysts recently issued reports on RNXT shares. Wall Street Zen lowered RenovoRx from a “hold” rating to a “strong sell” rating in a research report on Saturday, April 4th. Ascendiant Capital Markets raised their price target on shares of RenovoRx from $13.00 to $13.50 and gave the stock a “buy” rating in a research note on Thursday, April 9th. HC Wainwright reaffirmed a “buy” rating and set a $3.00 price target on shares of RenovoRx in a research note on Wednesday, April 8th. Finally, JonesTrading raised shares of RenovoRx to a “strong-buy” rating in a research note on Thursday, January 29th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $8.25.

Check Out Our Latest Stock Analysis on RNXT

RenovoRx Company Profile

(Get Free Report)

RenovoRx, Inc is a clinical-stage medical technology company focused on the development of proprietary drug-device combination therapies for the treatment of solid tumor malignancies. The company’s lead product candidate, RenovoCath™, is an intra-arterial catheter system designed to deliver high concentrations of chemotherapeutic agents directly to tumor sites while minimizing systemic exposure. RenovoRx seeks to improve clinical outcomes and reduce adverse effects by enhancing drug delivery precision in hard-to-treat cancers.

RenovoCath™ is being evaluated in multiple clinical trials targeting advanced pancreatic cancer and metastatic colorectal cancer, among other solid tumors.

Featured Stories

• Five stocks we like better than RenovoRx
• Viking Sails to All-Time Highs—Fundamentals Signal More to Come
• Datavalut Gains Traction: 5 Reasons to Sell Now
• TMC Stock: Why This Pre-Revenue Miner Is Worth Watching
• The Power Grid Is Dying—Is It Time to Buy Its Replacement?

Receive News & Ratings for RenovoRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RenovoRx and related companies with MarketBeat.com's FREE daily email newsletter.